Six months after taking the job and receiving a $1.1 million cash retention bonus, Andrew Long has stepped down as CEO of Chandler drugmaker Insys Therapeutics Inc., which continues to wind down its operations under bankruptcy protection.
Long's resignation, effective Oct. 23, was mentioned in an Oct. 25 U.S. Securities and Exchange Commission filing.
Long, who had served as Insys' chief financial officer since August 2017, took over in April from former CEO Saeed Motahari, who stepped down earlier that month.
Long also resigned from the company's board of directors, according to the filing.
